WO2025003976 - RECOMBINANT VIRUS-LIKE PARTICLES
National phase entry is expected:
Publication Number
WO/2025/003976
Publication Date
02.01.2025
International Application No.
PCT/IB2024/056308
International Filing Date
28.06.2024
Title **
[English]
RECOMBINANT VIRUS-LIKE PARTICLES
[French]
PSEUDO-PARTICULES VIRALES RECOMBINANTES
Applicants **
SEQIRUS INC.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Inventors
CAI, Yongfei
c/ Seqirus Inc.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Priority Data
63/510,970
29.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2343 | |
| EPO | Filing, Examination | 17861 | |
| Japan | Filing | 597 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 15880 |
Total: 37256 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to a recombinant virus-like particle (VLP) comprising an antigen for use as a vaccine. In an aspect, the present disclosure relates to a recombinant VLP comprising a capsid fusion protein for use as a vaccine.[French]
La présente divulgation concerne une pseudo-particule virale (VLP) recombinante comprenant un antigène destiné à être utilisé en tant que vaccin. Selon un aspect, la présente divulgation concerne une VLP recombinante comprenant une protéine de fusion de capside destinée à être utilisée en tant que vaccin.